Asian Market's Estimated Value Stocks For August 2026
As of August 2026, the Asian markets have been navigating a complex landscape marked by geopolitical tensions and evolving economic indicators. Amidst these challenges, investors are increasingly focused on identifying stocks that may be undervalued relative to their intrinsic worth, presenting potential opportunities for those seeking value in a volatile environment. In this context, understanding the fundamentals of what makes a stock potentially undervalued—such as strong financial health and growth prospects despite broader market uncertainties—can be crucial for making informed investment decisions.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| VINA TECHLtd (KOSDAQ:A126340) | ₩72900.00 | ₩140532.34 | 48.1% |
| Thonburi Healthcare Group (SET:THG) | THB7.75 | THB14.99 | 48.3% |
| Shoucheng Holdings (SEHK:697) | HK$1.705 | HK$3.29 | 48.2% |
| Shibaura Mechatronics (TSE:6590) | ¥4485.00 | ¥8733.36 | 48.6% |
| Netbay (SET:NETBAY) | THB11.50 | THB22.73 | 49.4% |
| Moshi Moshi Retail Corporation (SET:MOSHI) | THB39.25 | THB75.96 | 48.3% |
| Mao Geping Cosmetics (SEHK:1318) | HK$51.75 | HK$101.54 | 49% |
| ISU Petasys (KOSE:A007660) | ₩95600.00 | ₩190335.35 | 49.8% |
| gremsInc (TSE:3150) | ¥2502.00 | ¥4901.92 | 49% |
| C Sun Mfg (TWSE:2467) | NT$535.00 | NT$1050.10 | 49.1% |
Let's dive into some prime choices out of the screener.
Samsung Heavy Industries (KOSE:A010140)
Overview: Samsung Heavy Industries Co., Ltd. operates globally in shipbuilding, offshore, and energy infrastructure sectors, with a market cap of ₩19.05 trillion.
Operations: Samsung Heavy Industries' revenue is primarily derived from shipbuilding and marine engineering, amounting to ₩10.85 trillion, with an additional contribution of ₩455.64 billion from construction activities.
Estimated Discount To Fair Value: 26.6%
Samsung Heavy Industries is trading at ₩22,300, significantly below its estimated future cash flow value of ₩30,388.71, offering a potential value opportunity. Despite revenue growth forecasts of 12.2% per year being slower than the Korean market average of 14%, earnings are expected to grow substantially at 37.1% annually over the next three years. Recent strategic contracts like the floating data center project in the U.S. and Mozambique's Coral Norte FLNG project bolster its engineering capabilities and market position.
- Our comprehensive growth report raises the possibility that Samsung Heavy Industries is poised for substantial financial growth.
- Dive into the specifics of Samsung Heavy Industries here with our thorough financial health report.
Genscript Biotech (SEHK:1548)
Overview: Genscript Biotech Corporation is an investment holding company that manufactures and sells life science research products and services across the United States, Europe, Mainland China, Asia Pacific, and internationally, with a market cap of approximately HK$54.45 billion.
Operations: Genscript Biotech generates revenue through the manufacture and sale of life science research products and services across various regions including the United States, Europe, Mainland China, Asia Pacific, and other international markets.
Estimated Discount To Fair Value: 14.0%
Genscript Biotech, trading at HK$24.88, is undervalued by 14% compared to its estimated future cash flow value of HK$28.94. Despite a volatile share price and significant insider selling recently, the company is poised for above-average market growth with expected profitability in three years and revenue growth of 10.6% annually. Recent strategic partnerships, such as with Tamarind Bio for AI-driven molecular design validation, highlight potential advancements in drug discovery capabilities despite recent financial setbacks.
- Our earnings growth report unveils the potential for significant increases in Genscript Biotech's future results.
- Click here and access our complete balance sheet health report to understand the dynamics of Genscript Biotech.
Dexerials (TSE:4980)
Overview: Dexerials Corporation is a Japanese company that develops, manufactures, and sells electronic components, bonding materials, optics materials, and semiconductor products with a market cap of ¥534.60 billion.
Operations: The company's revenue is primarily derived from two segments: Optical Materials and Components, which generated ¥46.37 billion, and Electronic Materials and Components, contributing ¥69.41 billion.
Estimated Discount To Fair Value: 22.7%
Dexerials, trading at ¥3,191, is significantly undervalued based on discounted cash flow analysis with an estimated future value of ¥4,127.35. Despite recent share price volatility and a dividend not well covered by free cash flows, the company shows robust fundamentals with earnings growing 15.8% annually over five years and forecasts of 13.96% annual profit growth. Recent quarterly results show increased sales and net income compared to last year, supporting its growth trajectory.
- Insights from our recent growth report point to a promising forecast for Dexerials' business outlook.
- Delve into the full analysis health report here for a deeper understanding of Dexerials.
Next Steps
- Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 203 more companies for you to explore.Click here to unveil our expertly curated list of 206 Undervalued Asian Stocks Based On Cash Flows.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com